Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 5
2009 14
2010 18
2011 27
2012 35
2013 71
2014 115
2015 101
2016 149
2017 191
2018 212
2019 296
2020 424
2021 509
2022 536
2023 595
2024 206

Text availability

Article attribute

Article type

Publication date

Search Results

3,099 results

Results by year

Filters applied: . Clear all
Page 1
Dapagliflozin: A Review in Type 2 Diabetes.
Dhillon S. Dhillon S. Drugs. 2019 Jul;79(10):1135-1146. doi: 10.1007/s40265-019-01148-3. Drugs. 2019. PMID: 31236801 Free PMC article. Review.
Dapagliflozin (Forxiga()) is a highly potent, reversible and selective sodium-glucose cotransporter-2 inhibitor indicated worldwide for the treatment of type 2 diabetes (T2D). ...Dapagliflozin was generally well tolerated, with a low risk of hypoglycaemia; diabetic …
Dapagliflozin (Forxiga()) is a highly potent, reversible and selective sodium-glucose cotransporter-2 inhibitor indicated worldwide f …
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
Chertow GM, Vart P, Jongs N, Toto RD, Gorriz JL, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Stefánsson BV, Langkilde AM, Wheeler DC, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Chertow GM, et al. J Am Soc Nephrol. 2021 Sep;32(9):2352-2361. doi: 10.1681/ASN.2021020167. Epub 2021 Jul 16. J Am Soc Nephrol. 2021. PMID: 34272327 Free PMC article. Clinical Trial.
METHODS: Adults with eGFR of 25-75 ml/min per 1.73 m(2) and urinary albumin-to-creatinine ratio of 200-5000 mg/g had been randomized to receive dapagliflozin 10 mg/d or placebo. Here, we conducted a prespecified analysis of dapagliflozin's effects in patients …
METHODS: Adults with eGFR of 25-75 ml/min per 1.73 m(2) and urinary albumin-to-creatinine ratio of 200-5000 mg/g had been randomized to rece …
Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.
Provenzano M, Puchades MJ, Garofalo C, Jongs N, D'Marco L, Andreucci M, De Nicola L, Gorriz JL, Heerspink HJL; ROTATE-3 study group; ROTATE-3 study group members. Provenzano M, et al. J Am Soc Nephrol. 2022 Aug;33(8):1569-1580. doi: 10.1681/ASN.2022020207. Epub 2022 Apr 19. J Am Soc Nephrol. 2022. PMID: 35440501 Free PMC article. Clinical Trial.
UACR change during dapagliflozin or eplerenone treatment did not correlate with UACR change during dapagliflozin-eplerenone (r=-0.13; P=0.47; r=-0.08; P=0.66, respectively). Hyperkalemia was more frequently reported with eplerenone (n=8; 17.4%) compared with dapa …
UACR change during dapagliflozin or eplerenone treatment did not correlate with UACR change during dapagliflozin-eplerenone (r …
Pharmacokinetic Properties of Dapagliflozin in Hemodialysis and Peritoneal Dialysis Patients.
Barreto J, Borges C, Rodrigues TB, Jesus DC, Campos-Staffico AM, Nadruz W, Luiz da Costa J, Bueno de Oliveira R, Sposito AC. Barreto J, et al. Clin J Am Soc Nephrol. 2023 Aug 1;18(8):1051-1058. doi: 10.2215/CJN.0000000000000196. Epub 2023 May 25. Clin J Am Soc Nephrol. 2023. PMID: 37227937
No serious adverse events were reported for either group. Dapagliflozin recovered from dialysate corresponded to 0.10% of the administered dose. ...CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis …
No serious adverse events were reported for either group. Dapagliflozin recovered from dialysate corresponded to 0.10% of the adminis …
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
Wheeler DC, Toto RD, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Pecoits-Filho R, Correa-Rotter R, Rossing P, Sjöström CD, Umanath K, Langkilde AM, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Wheeler DC, et al. Kidney Int. 2021 Jul;100(1):215-224. doi: 10.1016/j.kint.2021.03.033. Epub 2021 Apr 18. Kidney Int. 2021. PMID: 33878338 Free article. Clinical Trial.
Dapagliflozin reduced the urinary albumin-to-creatinine ratio by 26% relative to placebo. Adverse events leading to study drug discontinuation were similar with dapagliflozin and placebo. There were fewer serious adverse events with dapagliflozin, and no new …
Dapagliflozin reduced the urinary albumin-to-creatinine ratio by 26% relative to placebo. Adverse events leading to study drug discon …
Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis.
Ghanim H, Abuaysheh S, Hejna J, Green K, Batra M, Makdissi A, Chaudhuri A, Dandona P. Ghanim H, et al. J Clin Endocrinol Metab. 2020 Apr 1;105(4):dgaa057. doi: 10.1210/clinem/dgaa057. J Clin Endocrinol Metab. 2020. PMID: 32044999 Clinical Trial.
CONTEXT: Dapagliflozin and other SGLT2 inhibitors are known to increase hematocrit, possibly due to its diuretic effects and hemoconcentration. ...Dapagliflozin treatment also caused a decrease in hypoxia-induced factor-1alpha expression in MNC while it increased th …
CONTEXT: Dapagliflozin and other SGLT2 inhibitors are known to increase hematocrit, possibly due to its diuretic effects and hemoconc …
Early Clinical Experience with Dapagliflozin in Children with Heart Failure.
Newland DM, Law YM, Albers EL, Friedland-Little JM, Ahmed H, Kemna MS, Hong BJ. Newland DM, et al. Pediatr Cardiol. 2023 Jan;44(1):146-152. doi: 10.1007/s00246-022-02983-0. Epub 2022 Aug 10. Pediatr Cardiol. 2023. PMID: 35948644
Dapagliflozin, when added to a background of guideline-directed medical therapy, appears well tolerated in children with HF. Larger studies are needed to evaluate safety and efficacy of dapagliflozin in this population....
Dapagliflozin, when added to a background of guideline-directed medical therapy, appears well tolerated in children with HF. Larger s …
Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome.
Urbanek K, Cappetta D, Bellocchio G, Coppola MA, Imbrici P, Telesca M, Donniacuo M, Riemma MA, Mele E, Cianflone E, Naviglio S, Conte E, Camerino GM, Mele M, Bucci M, Castaldo G, De Luca A, Rossi F, Berrino L, Liantonio A, De Angelis A. Urbanek K, et al. Pharmacol Res. 2023 Feb;188:106659. doi: 10.1016/j.phrs.2023.106659. Epub 2023 Jan 14. Pharmacol Res. 2023. PMID: 36646190 Free article.
Because the underlying mechanisms remain elusive, we investigated the effects of dapagliflozin on the progression of renal damage, using a model of non-diabetic cardiorenal disease. Dahl salt-sensitive rats were fed a high-salt diet for five weeks and then randomized to …
Because the underlying mechanisms remain elusive, we investigated the effects of dapagliflozin on the progression of renal damage, us …
Dapagliflozin Attenuates Contrast-induced Acute Kidney Injury by Regulating the HIF-1alpha/HE4/NF-kappaB Pathway.
Huang X, Guo X, Yan G, Zhang Y, Yao Y, Qiao Y, Wang D, Chen G, Zhang W, Tang C, Cao F. Huang X, et al. J Cardiovasc Pharmacol. 2022 Jun 1;79(6):904-913. doi: 10.1097/FJC.0000000000001268. J Cardiovasc Pharmacol. 2022. PMID: 35383661 Free PMC article.
We explored the role of the HIF-1alpha/HE4/NF-kappaB pathway in CI-AKI and how dapagliflozin effectively treats CI-AKI by inhibiting this pathway. In vitro, cells were divided into the control, hypoxia, hypoxia + dapagliflozin, and hypoxia + pSilencer-HIF-1alpha gro …
We explored the role of the HIF-1alpha/HE4/NF-kappaB pathway in CI-AKI and how dapagliflozin effectively treats CI-AKI by inhibiting …
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
Heerspink HJL, Kiyosue A, Wheeler DC, Lin M, Wijkmark E, Carlson G, Mercier AK, Åstrand M, Ueckert S, Greasley PJ, Ambery P. Heerspink HJL, et al. Lancet. 2023 Nov 25;402(10416):2004-2017. doi: 10.1016/S0140-6736(23)02230-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931629 Clinical Trial.
Zibotentan 1.5 mg plus dapagliflozin and zibotentan 0.25 mg plus dapagliflozin reduced UACR versus dapagliflozin plus placebo throughout the treatment period of the study. At week 12, the difference in UACR versus dapagliflozin plus placebo was -33.7% …
Zibotentan 1.5 mg plus dapagliflozin and zibotentan 0.25 mg plus dapagliflozin reduced UACR versus dapagliflozin plus p …
3,099 results